Waist circumference as the predominant contributor to the micro-inflammatory response in the metabolic syndrome: A cross sectional study

Journal of Inflammation

Volumn 7, Issue , 2010, Pages

  Rogowski, Ori ^a,b   Shapira, Itzhak ^a,b   Bassat, Orit Kliuk Ben ^a,b   Chundadze, Tamar ^a,b   Finn, Talya ^a,b   Berliner, Shlomo ^a,b   Steinvil, Arie ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONFOUNDING VARIABLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; WAIST CIRCUMFERENCE;

EID: 77954871039     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-7-35     Document Type: Article

References (41)

1. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? PM Ridker PW Wilson SM Grundy, Circulation 2004 109 2818 2825 10.1161/01.CIR.0000132467.45278.59 15197153
2. The metabolic syndrome, inflammation and cardiovascular disease in type 2 diabetes. AW Roberts M Evans, Current opinion in lipidology 2004 15 89 91 10.1097/00041433-200402000-00016 15166815
3. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. MK Rutter JB Meigs LM Sullivan RB D'Agostino Sr PW Wilson, Circulation 2004 110 380 385 10.1161/01.CIR.0000136581.59584.0E 15262834
4. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. BE Wisse, J Am Soc Nephrol 2004 15 2792 2800 10.1097/01.ASN.0000141966.69934.21 15504932
5. The metabolic syndrome, inflammation, and risk of cognitive decline. K Yaffe A Kanaya K Lindquist EM Simonsick T Harris RI Shorr FA Tylavsky AB Newman, Jama 2004 292 2237 2242 10.1001/jama.292.18.2237 15536110
6. The metabolic syndrome in obese postmenopausal women: relationship to body composition, visceral fat, and inflammation. T You AS Ryan BJ Nicklas, The Journal of clinical endocrinology and metabolism 2004 89 5517 5522 10.1210/jc.2004-0480 15489217
7. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. JS Yudkin I Juhan-Vague E Hawe SE Humphries G di Minno M Margaglione E Tremoli T Kooistra PE Morange P Lundman, et al. Metabolism: clinical and experimental 2004 53 852 857 15254876
8. Young adult obese subjects with and without insulin resistance: what is the role of chronic inflammation and how to weigh it non-invasively? G Tarantino P Colicchio P Conca C Finelli MN Di Minno M Tarantino D Capone F Pasanisi, Journal of inflammation (London, England) 2009 6 6 19291292
9. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. R Nesto, Diabet Med 2004 21 810 817 10.1111/j.1464-5491. 2004.01296.x 15270782
10. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. SM Boekholdt CE Hack MS Sandhu R Luben SA Bingham NJ Wareham RJ Peters JW Jukema NE Day JJ Kastelein KT Khaw, Atherosclerosis 2006 187 415 422 10.1016/j.atherosclerosis.2005.09.023 16257408 (Pubitemid 43963024)
11. Inflammatory markers and the risk of coronary heart disease in men and women. JK Pai T Pischon J Ma JE Manson SE Hankinson K Joshipura GC Curhan N Rifai CC Cannuscio MJ Stampfer EB Rimm, The New England journal of medicine 2004 351 2599 2610 10.1056/NEJMoa040967 15602020 (Pubitemid 39628581)
12. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. PM Ridker E Danielson FA Fonseca J Genest AM Gotto Jr JJ Kastelein W Koenig P Libby AJ Lorenzatti JG MacFadyen, et al. The New England journal of medicine 2008 359 2195 2207 10.1056/NEJMoa0807646 18997196
13. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. PM Ridker, American heart journal 2004 148 19 26 10.1016/j.ahj.2004.04.028 15211329
14. Inflammation markers and erythrocyte sedimentation rate but not metabolic syndrome factor score predict coronary heart disease in high socioeconomic class males: the HDDRISC study. IF Godsland R Bruce JA Jeffs F Leyva C Walton JC Stevenson, International journal of cardiology 2004 97 543 550 10.1016/j.ijcard.2004.05.008 15561346
15. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. ES Ford, Atherosclerosis 2003 168 351 358 10.1016/S0021-9150(03)00134-5 12801619
16. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). P Muntner J He J Chen V Fonseca PK Whelton, Annals of epidemiology 2004 14 686 695 10.1016/j.annepidem.2004.01.002 15380800
17. Heart rate and microinflammation in men: a relevant atherothrombotic link. O Rogowski I Shapira A Shirom S Melamed S Toker S Berliner, Heart (British Cardiac Society) 2007 93 940 944 17237129
18. Values of high-sensitivity C-reactive protein in each month of the year in apparently healthy individuals. O Rogowski S Toker I Shapira S Melamed A Shirom D Zeltser S Berliner, The American journal of cardiology 2005 95 152 155 10.1016/j.amjcard.2004.08.086 15619418
19. Relation of educational level to inflammation-sensitive biomarker level. A Steinvil A Shirom S Melamed S Toker D Justo N Saar I Shapira S Berliner O Rogowski, The American journal of cardiology 2008 102 1034 1039 10.1016/j.amjcard.2008.05.055 18929705
20. Elevated resting heart rate is associated with the metabolic syndrome. O Rogowski A Steinvil S Berliner M Cohen N Saar OK Ben-Bassat I Shapira, Cardiovasc Diabetol 2009 8 55 10.1186/1475-2840-8-55 19828043
21. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. MA van de Ree MV Huisman HM Princen AE Meinders C Kluft, Atherosclerosis 2003 166 129 135 10.1016/S0021-9150(02)00316-7 12482559
22. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. AD Pradhan BM Everett NR Cook N Rifai PM Ridker, Jama 2009 302 1186 1194 10.1001/jama.2009.1347 19755697
23. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. DJ Stocker AJ Taylor RW Langley MR Jezior RA Vigersky, American heart journal 2007 153 445 e441-446 10.1016/j.ahj.2006.11.005 17307426
24. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. SM Haffner AS Greenberg WM Weston H Chen K Williams MI Freed, Circulation 2002 106 679 684 10.1161/01.CIR.0000025403.20953.23 12163427
25. Prevalence and risk factors for asymptomatic bacteriuria in women with Type 2 diabetes mellitus. A Ishay I Lavi R Luboshitzky, Diabet Med 2006 23 185 188 10.1111/j.1464-5491.2005.01758.x 16433717
26. Inflammatory process in type 2 diabetes: The role of cytokines. K Alexandraki C Piperi C Kalofoutis J Singh A Alaveras A Kalofoutis, Annals of the New York Academy of Sciences 2006 1084 89 117 10.1196/annals.1372.039 17151295
27. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. A Clauss, Acta Haematol Basel 1957 17 237 246 10.1159/000205234
28. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. N Rifai RP Tracy PM Ridker, Clinical chemistry 1999 45 2136 2141 10585345
29. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama 2001 285 2486 2497 10.1001/jama.285.19.2486 11368702
30. Follow-up report on the diagnosis of diabetes mellitus. S Genuth KG Alberti P Bennett J Buse R Defronzo R Kahn J Kitzmiller WC Knowler H Lebovitz A Lernmark, et al. Diabetes care 2003 26 3160 3167 10.2337/diacare.26.12.3331 14578255
31. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. SM Grundy JI Cleeman SR Daniels KA Donato RH Eckel BA Franklin DJ Gordon RM Krauss PJ Savage SC Smith Jr, et al. Circulation 2005 112 2735 2752 10.1161/CIRCULATIONAHA.105.169404 16157765
32. Inflammation, hypertension, and the metabolic syndrome. SM Grundy, Jama 2003 290 3000 3002 10.1001/jama.290.22.3000 14665663
33. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. SM Grundy JI Cleeman CN Merz HB Brewer Jr LT Clark DB Hunninghake RC Pasternak SC Smith Jr NJ Stone, Circulation 2004 110 227 239 10.1161/01.CIR.0000133317.49796.0E 15249516
34. Inflammation, the metabolic syndrome and cardiovascular risk. RP Tracy, International journal of clinical practice 2003 10 17 12793593
35. Low-grade inflammation in individuals with the hypertriglyceridemic waist phenotype: another feature of the atherogenic dysmetabolism. O Rogowski I Shapira A Steinvil S Berliner, Metabolism: clinical and experimental 2009 58 661 667 19375589
36. C-reactive protein: risk marker or mediator in atherothrombosis? I Jialal S Devaraj SK Venugopal, Hypertension 2004 44 6 11 10.1161/01.HYP.0000130484. 20501.df 15148294
37. Leukocyte count and coronary heart disease: implications for risk assessment. M Madjid I Awan JT Willerson SW Casscells, Journal of the American College of Cardiology 2004 44 1945 1956 10.1016/j.jacc.2004.07.056 15542275
38. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. J Arnlov E Ingelsson J Sundstrom L Lind, Circulation 2010 121 230 236 10.1161/CIRCULATIONAHA.109.887521 20038741
39. The JUPITER trial: results, controversies, and implications for prevention. PM Ridker, Circ Cardiovasc Qual Outcomes 2009 2 279 285 10.1161/CIRCOUTCOMES.109.868299 20031849
40. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. K Clement N Viguerie C Poitou C Carette V Pelloux CA Curat A Sicard S Rome A Benis JD Zucker, et al. Faseb J 2004 18 1657 1669 10.1096/fj.04-2204com 15522911
41. Effects of obesity surgery on the metabolic syndrome. WJ Lee MT Huang W Wang CM Lin TC Chen IR Lai, Arch Surg 2004 139 1088 1092 10.1001/archsurg.139. 10.1088 15492149